For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

Hexarelin vs Mod-GRF(1-29)

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

HexarelinMod-GRF(1-29)
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asExamorelin, EP 23905, MF-6003Modified GRF(1-29), CJC-1295 without DAC, Tetrasubstituted GRF, Sermorelin analog
EvidencePreclinical onlyResearch-stage
Dosing range50mcg–200mcg mcg, 1–3x daily (cycling recommended to prevent desensitization)100mcg–200mcg mcg, 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking)
AdministrationSubcutaneous injection, Intramuscular injectionSubcutaneous injection, Intramuscular injection
Key side effectsCortisol elevation, Prolactin elevation, Water retention, Increased appetiteWater retention (mild, dose-dependent), Tingling / numbness in extremities (carpal tunnel-like at high doses), Increased appetite (via GHRP component — less with Mod-GRF alone), Flushing or warmth at injection site
Cited sources1 reference2 references

Key differences

  • Evidence level differs: Hexarelin is preclinical only, while Mod-GRF(1-29) is research-stage.
  • Frequency: Hexarelin is typically 1–3x daily (cycling recommended to prevent desensitization); Mod-GRF(1-29) is 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking).
  • Research depth: this profile cites 1 source for Hexarelin vs 2 for Mod-GRF(1-29).

How each works

Hexarelin

Hexarelin produces dose-dependent GH release significantly greater than GHRP-6 or Ipamorelin. It also has direct cardioprotective effects via CD36 receptor binding, independent of GH — making it unique among GHRPs. Studies show protection from ischemic cardiac injury and myocardial fibrosis reduction in animal models. Desensitization occurs with chronic continuous use.

Mod-GRF(1-29)

Native GHRH(1-29) is rapidly cleaved by plasma dipeptidyl peptidase IV (DPP-IV) within 2–3 minutes. Mod-GRF(1-29) incorporates four amino acid substitutions (positions 2, 8, 15, 27) that resist DPP-IV degradation, extending the half-life to approximately 30 minutes while preserving GHRH receptor binding affinity. This creates a half-life window aligned with physiological GH pulsatility, making it suitable for 2–3x daily injections that mimic natural GH release patterns.

Read the full Hexarelin profileRead the full Mod-GRF(1-29) profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.